Dog,

The increase in additional shares provides Cardiogenics the wherewithal to address strategic management options beyond the near term need to raise operating cash. IMO nothing nefarious regards this increase in authorized shares; most likely the company is ensuring it has enough authorized shares to address whatever Corporate Management needs that could arise should the commercial potential of the company's patented technology become obvious to the investment community as I have described in previous posts on Agoracom and Raging Bull.

Ante